Dr. Renschler Discusses Updated Results of the MPACT Study

Markus Renschler, MD
Published: Friday, Jun 20, 2014

Markus Renschler, MD, vice president, global head, Hematology Oncology Medical Affairs at Celgene, discusses updated results of the MPACT study, which examined nab-paclitaxel plus gemcitabine versus gemcitabine for patients with metastatic pancreatic cancer.

Renschler says the updated analysis shows a statistically significant improvement in overall survival (6.6 months to 8.7 months) in patients who received both nab-paclitaxel and gemcitabine.

The data also shows a tail at the end of the survival curve, Renschler says. The 2-year survival rate doubled from 5% to 10% and there are now 4-year survivals in the nab-paclitaxel gemcitabine arm.

Markus Renschler, MD, vice president, global head, Hematology Oncology Medical Affairs at Celgene, discusses updated results of the MPACT study, which examined nab-paclitaxel plus gemcitabine versus gemcitabine for patients with metastatic pancreatic cancer.

Renschler says the updated analysis shows a statistically significant improvement in overall survival (6.6 months to 8.7 months) in patients who received both nab-paclitaxel and gemcitabine.

The data also shows a tail at the end of the survival curve, Renschler says. The 2-year survival rate doubled from 5% to 10% and there are now 4-year survivals in the nab-paclitaxel gemcitabine arm.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Integrating Novel Targeted Treatment Strategies to Advance Pancreatic Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x